Topical bromfenac for post-cataract extraction: A systematic review and pooled analysis

European Journal of Inflammation

Letters to the editor

W Hu¹  J-J Li¹  Y-T Wang¹  H-H Wu²  M-Z Zhai³  Z-S Gao⁴  L-P Jiang⁵  Y Liu⁶ 

[1] Department of Emergency, Xi’jing Hospital, Fourth Military Medical University, Xi’an, PR China;Department of Emergency, Xi’jing Hospital, Fourth Military Medical University, Xi’an, PR China;Department of Anesthesiology, Fuzhou General Hospital of Nanjing Military Region, Fuzhou, PR China;Department of Emergency, Xi’jing Hospital, Fourth Military Medical University, Xi’an, PR China;Department of Medical Psychology, Fourth Military Medical University, Xi’an, PR China;Department of Ophthalmology, Second People’s Hospital of Shanxi Province, Xi’an, PR China;Department of Ophthalmology, the Second People’s Hospital of Rongcheng, Rongcheng, PR China;Department of Outpatient, Xi’jing Hospital, Fourth Military Medical University, Xi’an, PR China;

关键词: bromfenac;    cataract extraction;    meta-analysis;   

DOI  :  10.1177/1721727X15601732

 received in 2015-05-26, accepted in 2015-07-27,  发布年份 2015

来源: Sage Journals

【 摘 要 】

Bromfenac, a promising ophthalmic non-steroidal anti-inflammatory drug, has been used once daily for postoperative ocular inflammation and pain with satisfying efficacy, however, no integrated conclusion on its safety in clinical settings has been drawn. The purpose of this pooled analysis is to investigate the safety and efficacy of once daily bromfenac for ocular inflammation and pain among patients after cataract extraction (CE). MEDLINE, PsycINFO, Scopus, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched from inception to September 2014. Randomized controlled trials (RCTs) that studied topical bromfenac after CE were analyzed. Included studies were systemically reviewed, and effects were summarized using odds ratio (OR) with suitable effect model. Four RCTs involving 2294 participants were included. Topical bromfenac significantly increased the proportion of cleared ocular inflammation (OR, 2.37; 95% confidence interval [CI], 1.83–3.07; P <0.00001), ocular pain free (OR, 5.14; 95% CI, 4.07–6.49; P <0.00001), and decreased risk of overall adverse events (OR, 0.47; 95% CI, 0.38–0.58; P <0.00001). Bromfenac has been shown to be a safe and effective treatment for postoperative pain and inflammation in subjects undergoing CE. This is evidenced by the lower incidence of adverse events and the low scores for ocular pain and inflammation across multiple RCTs. However, demographics, co-morbidities of study participants, and the amount of co-medication were not reported, these possible sources of heterogeneity should be examined in future clinical trials.

【 授权许可】

Unknown   
© The Author(s) 2015